Journal of Antimicrobial Chemotherapy (1991) 27, 589-598
© 1991 The British Society for Antimicrobial Chemotherapy
research-article |
Antibacterial activity of lomefloxacin
Department of Microbiology, Wycombe General Hospital High Wycombe, Bucks HP 11 2TT, UK
Received 5 October 1990; accepted 25 January 1991
0Lomefloxacin has marked activity against Gram-negative bacilli including Enterobacteriaceae, non-fermenting strains and Haemophilus influenzae with 98% of all isolates tested having MICs of 0·25 mg/l or less. Sixty-eight per cent of Pseudomonas aeruginosa strains were sensitive to 1 mg/l with a few strains resistant to 8 or 16 mg/l. Gram-positive cocci were more resistant, particularly streptococci, where the MICs vary between 1 and 8 mg/l. Bactericidal activity was similar to inhibitory activity and the effect of increasing serum concentrations and bacterial inocula was minimal. The MIC and MBC were increased in the presence of urine, particularly at an acid pH 5. Comparative MICs showed that lomefloxacin was more active than ofloxacin and pefloxacin, similar to norfloxacin but less active than ciprofloxacin for Gram-negative bacteria but not for Gram-positive cocci.
Comparative studies with sensitivity disc concentrations snowed that a 5 µg disc was more satisfactory than the 10 µg disc as the zone sizes were more suitable for routine testing.
Solutions of lomefloxacin showed instability in bright sunlight when 52% of activity was lost in 1 h. Similar instability was shown in impregnated discs which lost up to 40% activity in 6 h exposure.
Lomefloxacin showed a wide range of activity against Gram-negative bacteria including multiresistant strains and Pseudomonas spp. Gram-positive bacteria were less susceptible, with streptococci more resistant than staphylococci. Lomefloxacin is well absorbed after oral administration giving high blood and urine concentrations and its prolonged half-life means once daily dosing in the treatment of many types of bacterial infection may be possible.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. B. Washington, S. Y. E. Hou, C. Campanella, N. Hughes, S. Brown, and B. Berner Pharmacokinetics and Pharmacodynamics of a Novel Extended-Release Ciprofloxacin in Healthy Volunteers J. Clin. Pharmacol., November 1, 2005; 45(11): 1236 - 1244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. E. Wagenlehner, S. Wydra, H. Onda, M. Kinzig-Schippers, F. Sorgel, and K. G. Naber Concentrations in Plasma, Urinary Excretion, and Bactericidal Activity of Linezolid (600 Milligrams) versus Those of Ciprofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3789 - 3794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Naber, U. Theuretzbacher, M. Kinzig, O. Savov, and F. Sörgel Urinary Excretion and Bactericidal Activities of a Single Oral Dose of 400 Milligrams of Fleroxacin versus a Single Oral Dose of 800 Milligrams of Pefloxacin in Healthy Volunteers Antimicrob. Agents Chemother., July 1, 1998; 42(7): 1659 - 1665. [Abstract] [Full Text]
|
|